However, cancer cells can also present constitutive PD-L1 expression as a consequence of multiple mechanisms driven by oncogene mutations or the loss/inactivation of tumor suppressors (e.g., PTEN mutations), leading to the activation of key intracellular cascades, such as the JAK/STAT3, [115] the PI3K/AKT/mTOR, or the ERK1/2 pathways [44,116]. The gene discussed is CD274; the disease is cancer.